Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Impedance Combination01:21

Impedance Combination

757
Consider a string of christmas lights, each bulb symbolizing an impedance element. In this series configuration, the flow of electric current remains uniform across every component. This behavior aligns with Kirchhoff's Voltage Law (KVL), which asserts that the total impedance in such a setup equals the sum of individual impedances—akin to resistors in series. It follows that the voltage from the power source is distributed proportionally among these components, adhering to the voltage...
757
Combination Of Resistors01:18

Combination Of Resistors

4.0K
Electrical devices in any circuit can be connected either by series or parallel connections. Additionally, circuits can be connected involving both of these connections, known as combination or complex circuits. As these circuits have complex resistor connections, it is necessary to identify different parts as either series or parallel connections, then the whole combination of series and parallel resistors can be reduced to a single equivalent resistance. With the known equivalent resistance...
4.0K
Combining Functions01:16

Combining Functions

243
Functions can be combined to form new mathematical models that describe interactions between variables. These combinations are fundamental in understanding relationships between changing quantities and are commonly encountered in scientific and engineering contexts. The combination methods—addition, subtraction, multiplication, division, and composition—each have unique implications for the resulting function’s domain and behavior.When combining functions through arithmetic...
243
Stresses under Combined Loadings01:23

Stresses under Combined Loadings

485
When analyzing a bent tube with a circular cross-section subjected to multiple forces, it is crucial to determine the stress distribution in order to maintain structural integrity under varied load conditions.
The process begins by slicing the tube at critical points and analyzing the internal forces and stress components at these sections, focusing on the centroid. Normal stresses, generated by axial forces and bending moments, are either compressive or tensile and vary across the section from...
485
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

Journal for immunotherapy of cancer·2026
Same author

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50.

Cancer cell international·2026
Same author

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.

NPJ precision oncology·2026
Same author

FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Related Experiment Video

Updated: Feb 7, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Immunotherapy-based combinations: an update.

Giovanni Fucà1, Filippo de Braud1,2, Massimo Di Nicola1

  • 1Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori.

Current Opinion in Oncology
|July 12, 2018
PubMed
Summary
This summary is machine-generated.

Cancer immunotherapy combining immune checkpoint blockade (ICB) with other therapies shows promise. Novel combinations are improving outcomes in lung, kidney, and skin cancers, establishing new standards of care.

More Related Videos

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.6K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.7K

Related Experiment Videos

Last Updated: Feb 7, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.6K
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.7K

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Immunotherapy, particularly immune checkpoint blockade (ICB), has transformed cancer treatment.
  • A significant proportion of patients do not respond consistently to current ICB therapies.

Purpose of the Study:

  • To review innovative and clinically promising ICB-based combination strategies.
  • To highlight approaches aimed at enhancing the efficacy of cancer immunotherapy.

Main Methods:

  • Review of recent clinical trial data and scientific literature.
  • Analysis of combination therapies involving ICB with chemotherapy, antiangiogenics, and targeted agents.
  • Evaluation of sequential and concurrent treatment regimens.

Main Results:

  • First-line ipilimumab and nivolumab demonstrate superiority in metastatic non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).
  • Combination of PD-1/PD-L1 blockade with antiangiogenics (e.g., bevacizumab and atezolizumab) shows efficacy in metastatic RCC.
  • Sequential chemoradiotherapy followed by durvalumab maintenance is a new standard for advanced NSCLC.
  • Addition of pembrolizumab to chemotherapy improves survival in metastatic NSCLC.
  • Combinations with BRAF/MEK or EGFR inhibitors show promise in melanoma and NSCLC but face safety challenges.

Conclusions:

  • Immunotherapy combinations are increasingly becoming the standard of care for advanced cancers.
  • These combinations are particularly impactful in melanoma, NSCLC, and RCC.
  • Ongoing research focuses on optimizing combination strategies to overcome resistance and improve patient outcomes.